Comparative Pharmacology
Head-to-head clinical analysis: PERGOLIDE MESYLATE versus ROPINIROLE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERGOLIDE MESYLATE versus ROPINIROLE HYDROCHLORIDE.
PERGOLIDE MESYLATE vs ROPINIROLE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergoline-derived dopamine D2 receptor agonist; also activates D1 and D3 receptors, and has antagonist activity at α2-adrenergic and 5-HT2B receptors.
Ropinirole is a non-ergoline dopamine agonist with high affinity for D2 and D3 dopamine receptors, particularly D3. It stimulates postsynaptic dopamine receptors in the striatum, compensating for dopamine deficiency in Parkinson's disease and modulating dopaminergic pathways in restless legs syndrome.
0.05 mg orally once daily for first 2 days, then increase by 0.1-0.15 mg/day every 3 days over 12 days, then by 0.25 mg/day every 3 days until optimal response; usual therapeutic range 2-3 mg/day divided 3 times daily; maximum 5 mg/day.
Initial: 0.25 mg orally three times daily; titrate weekly by increments of 0.25 mg three times daily up to 1 mg three times daily, then 0.5 mg three times daily up to 3 mg three times daily; maximum 8 mg three times daily (24 mg/day).
None Documented
None Documented
Terminal elimination half-life: 15-27 hours (mean 21 hours); clinically relevant for once-daily dosing
Terminal elimination half-life: 5-6 hours in young healthy adults; 6-8 hours in elderly. Clinically, steady-state achieved within 2 days.
Renal: 50-60% as metabolites; Fecal: 40-50%; Biliary: minor (<5%)
Renal: 88% (primarily as metabolites, <10% unchanged). Fecal: <5%.
Category C
Category A/B
Dopamine Agonist
Dopamine Agonist